A safer vaccine for Alzheimer’s disease?
- 1 November 2002
- journal article
- review article
- Published by Elsevier in Neurobiology of Aging
- Vol. 23 (6), 1001-1008
- https://doi.org/10.1016/s0197-4580(02)00124-0
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- Reduced levels of amyloid β-peptide antibody in Alzheimer diseaseNeurology, 2001
- Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2001
- Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapyNature Medicine, 2001
- Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer diseaseNature Medicine, 2000
- Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerizationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2000
- High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregationJournal of Neuroimmunology, 1999
- N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodiesJournal of Neuroimmunology, 1998
- Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor proteinNature, 1995
- Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.The Journal of Experimental Medicine, 1993
- Alzheimer's Disease from the Perspective of the Systemic and Localized Forms of AmyloidosisBrain Pathology, 1991